2,4-二氯-5-硝基-6-甲基嘧啶 | 13162-26-0

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2,4-二氯-5-硝基-6-甲基嘧啶
• 中文别名: 2,4-二氯-6-甲基-5-硝基嘧啶；2,4-二氯-5-硝基6-甲基嘧啶；2,4-二氯-5-硝基-6甲基嘧啶
• 英文名称: 2,4-dichloro-6-methyl-5-nitropyrimidine
• 英文别名: 2,6-Dichlor-5-nitro-4-methyl-pyrimidin；5-nitro-6-methyl-2,4-dichloropyrimidine
• CAS: 13162-26-0
• 化学式: C₅H₃Cl₂N₃O₂
• mdl: MFCD00023196
• 分子量: 208.004
• InChiKey: NBCOZXBHPKSFSA-UHFFFAOYSA-N

物化性质

• 熔点：
  52-54°C
• 沸点：
  135-136 °C(Press: 22 Torr)
• 密度：
  1.626±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：

  Sensitive to moisture

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S39
• 危险类别码：
  R36/37/38,R41,R22
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C 冰箱，处于惰性气氛中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,4-Dichloro-6-methyl-5-nitropyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,4-Dichloro-6-methyl-5-nitropyrimidine
CAS number: 13162-26-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3Cl2N3O2
Molecular weight: 208.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用作医药中间体

反应信息

• 作为反应物：
  描述：

  2,4-二氯-5-硝基-6-甲基嘧啶 在 溴 、 sodium acetate 、 溶剂黄146 作用下， 以 二甲基亚砜 、 Petroleum ether 为溶剂， 反应 0.83h， 生成 [2,6-bis(benzylamino)-5-nitropyridin-4-yl]acetonitrile
  参考文献：
  名称：

  2,6-二氨基-9-苄基-9-脱氮嘌呤和相关化合物的合成及其抗增殖活性。

  摘要：

  用KCN处理6-溴甲基-或6-二溴甲基-5-硝基嘧啶-2,4-二胺得到相同的产物-（2,6-二氨基-5-硝基嘧啶基）乙腈。腈在α-碳上苯甲酰化为氰基，优先提供相应的单苄基和二苄基衍生物，其还原环化反应生成7-苄基-5H-吡咯并[3,2-d]嘧啶-2,4-二胺和7,7-二苄基-7H-吡咯并[3,2-d]嘧啶-2,4,6-三胺。还研究了用苄基，乙酰基或苯甲酰基保护N（2）和N（4）原子的适用性。体外评估CCRF-CEM，HL-60，HeLa S3和L1210细胞系对细胞生长的抑制作用在8种新化合物中显示出显着活性。最有效的化合物是上述6-二溴甲基衍生物（IC（50）= 0.54、1.7、5.0和1.9 molL（-1））和7，

  DOI：

  10.1016/j.bmc.2004.04.003
• 作为产物：
  描述：

  6-甲基尿嘧啶 在 硫酸 、 四丁基氯化铵 、 硝酸 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 生成 2,4-二氯-5-硝基-6-甲基嘧啶
  参考文献：
  名称：

  新型2,4-二芳基-6-甲基-5-硝基嘧啶的合成作为抗菌剂和抗氧化剂

  摘要：

  通过Suzuki-Miyaura偶联2,4以高收率合成了一系列新的2,4-二芳基-6-甲基-5-硝基嘧啶（5a，5b，5c，5d，5e，5f，5g，5h，5i）。二氯6甲基5硝基嘧啶（3）与各种芳基硼酸酯（4a，4b，4c，4d，4e，4f，4g，4h，4i）在1,1'-双（二苯基膦基）二茂铁二氯钯（II）（Pd（dppf）2 Cl 2）存在下。此外，针对标题化合物5a，5b，5c，5d，5e，5f，5g，5h，5i筛选了抗菌和抗氧化性能。大多数化合物对革兰氏阳性菌金黄色葡萄球菌和枯草芽孢杆菌以及革兰氏阴性菌大肠杆菌和肺炎克雷伯菌具有显着活性。。与维生素C相比，标题化合物的抗氧化活性显示出显着的抗氧化活性。

  DOI：

  10.1002/jhet.1645

文献信息

• [EN] NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016037578A1

  公开（公告）日：2016-03-17

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，这些化合物是重排转位过程中的抑制剂（RET）激酶，包含它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病和/或与RET功能障碍相关的疾病或调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道氏综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和食管胃交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• [EN] PTERIDINE DERIVATIVES AS MODULATORS OF ROR GAMMA<br/>[FR] DÉRIVÉS DE PTÉRIDINE EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017058831A1

  公开（公告）日：2017-04-06

  The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

  本发明涵盖了式（I）化合物，其中变量如本文所定义，适用于调节RORγ并治疗与调节RORγ相关的疾病。本发明还涵盖了制备式（I）化合物的方法和含有它们的药物制剂。
• Addition of Lithiated 9-Deazapurine Derivatives to a Carbohydrate Cyclic Imine:  Convergent Synthesis of the Aza-<i>C</i>-nucleoside Immucillins
  作者：Gary B. Evans、Richard H. Furneaux、Tracy L. Hutchison、Hollis S. Kezar、Philip E. Morris,、Vern L. Schramm、Peter C. Tyler

  DOI：10.1021/jo0155613

  日期：2001.8.1

  Means have been developed for the synthesis and addition of 9-deaza-9-lithiopurine derivatives to the carbohydrate-derived cyclic imine 6 in facile convergent syntheses of biologically active aza-C-nucleosides.

  已经开发了在生物活性氮杂-C-核苷的容易会聚合成中将9-脱氮基-9-硫代嘌呤衍生物合成和添加至碳水化合物衍生的环亚胺6的方法。
• [EN] PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA<br/>[FR] DÉRIVÉS DE PYRIDINE ET DE PYRIMIDINE ET LEUR UTILISATION POUR TRAITER OU PRÉVENIR LA GRIPPE, OU POUR ATTÉNUER SES SYMPTÔMES
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：WO2017133657A1

  公开（公告）日：2017-08-10

  Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer,or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

  本文提供的是一种化合物，其化学式为(I)，可以是药用盐、溶剂合物、多型体、前药、共药、共晶体、互变异构体、消旋体、对映体或二对映体，或它们的混合物形式，可用于治疗、改善或预防流感。
• Study on the preparation of heteroaryl substituted enamines. A simple synthesis of heteroaryl substituted acetaldoximes from enamines
  作者：Antončopar、Branko Stanovnik、Miha Tišler

  DOI：10.1002/jhet.5570330240

  日期：1996.3

  tert-butoxybis(dimethylamino)methane was carried out on methyl substituted six-membered nitrogen containing heterocycles 1 to give enamines 2, which were easily transformed to oximes by treating with hydroxylamine hydrochloride in methanol. Most of them were isolated as (E, Z)-oximes of heteroarylacetaldehyde (11), but 5-(1,2,4-triazinyl) substituted derivatives as (E, Z)-oximes of 2,5-dihydro-1,2,4-triaz

  对甲基取代的六元含氮杂环1进行了甲基对N，N-二甲基甲酰胺二甲基乙缩醛和叔丁氧基双（二甲基氨基）甲烷反应性的比较研究，得到烯胺2，烯胺2易被环己酮转化为肟在甲醇中用盐酸羟胺处理。它们中的大多数被分离为杂芳基乙醛（11）的（E，Z）-肟，但5-，1,2,4-三嗪基）取代的衍生物被2,5,2-二氢-1 （E，Z）-肟取代， 2,4-三嗪-（Z）-5-亚甲基乙醛（11t，11u和12）。肟最终被转化为相应的乙腈16和3-（二甲基氨基）丙烯腈17。